Citations

Clear

9383 citation(s) found for "Thomas, PS".

Guidelines for Controlled Trials of Prophylactic Treatment of Chronic Migraine in Adults
Silberstein, Stephen D., Tfelt‐Hansen, Peer , Dodick, DW, Limmroth, Volker , Lipton, RB, Wang, S. J., Lipton, RB, Pascual, Julio

Mayo Clinic

Cephalalgia | February 20, 2008 | Volume: 28 | Issue: 5 | Pages: 484-495

10.1111/j.1468-2982.2008.01555.x | PMID 18294250 Get It

In 1991 the Clinical Trials Subcommittee of the International Headache Society (IHS) developed and published its first edition of the Guidelines on controlled trials of drugs in episodic migraine because only quality trials can form the basis for international collaboration on drug therapy, and these Guidelines would ‘improve the quality of controlled clinical trials in migraine’. With the current trend for large multinational trials, there is a need for increased awareness of methodological issues in clinical trials of drugs and other treatments for chronic migraine. These Guidelines are intended to assist in the design of well-controlled clinical trials of chronic migraine in adults, and do not apply to studies in children or adolescents.
Phase I Clinical Study of Atacicept in Patients with Relapsed and Refractory B-Cell Non–Hodgkin's Lymphoma
Ansell, Stephen M. , Inwards, David J. , Porrata, Luis F. , Ythier, A., Ferrande, Lee, Nestorov, Ivan , DeVries, Todd , Dillon, Stacey R. , Hausman, Diana F., Novak, Anne J. , Witzig, Thomas E.

Mayo Clinic

Clinical Cancer Research | February 15, 2008 | Volume: 14 | Issue: 4 | Pages: 1105-1110

10.1158/1078-0432.ccr-07-4435 | PMID 18281543 Get It

Abstract Purpose: B-lymphocyte stimulator and a proliferation-inducing ligand regulate B-cell homeostasis and immunoglobulin production and are overexpressed in B-cell malignancies. Atacicept (TACI-Ig), a recombinant fusion protein that inhibits both B-lymphocyte stimulator and a proliferation-inducing ligand, may be a novel treatment for B-cell malignancies. Experimental Design: A phase 1, open-label, dose-escalation study of atacicept in patients with relapsed or refractory B-cell lymphoma was done. Atacicept was given s.c. weekly for 5 weeks to sequential patient cohorts at doses of 2, 4, 7, or 10 mg/kg. Patients responding or with stable disease were eligible for treatment on an extension study for up to 24 weeks or until disease progression. Results: All patients were heavily pretreated (median number of previous treatments, 5; range, 1-10), and four patients had previously received a stem cell transplant. Four patients were treated at the 2, 4, or 7 mg/kg dose levels, and three patients received 10 mg/kg of atacicept. Atacicept was well tolerated at all doses. Three adverse events with grade 3 severity were reported for one patient, including jaw pain, gastrointestinal hemorrhage, and sepsis; all were considered unrelated to atacicept. Pharmacokinetic results were nonlinear, and treatment with atacicept resulted in dose-dependent decreases in immunoglobulin concentrations. Two patients had stable disease at 8 weeks, entered the extension study, and received additional doses of atacicept with no safety or tolerability concerns. Conclusion: Atacicept at doses of up to 10 mg/kg was well tolerated and showed biological activity by decreasing immunoglobulin concentrations, although tumor responses were not observed.
Bone Growth and Turnover in Progesterone Receptor Knockout Mice
Rickard, David J., Evans, Glenda L., Hefferan, Theresa E., Hunter, Jamie C., Waters, Katrina M. , O’Malley, Bert W. , Khosla, Sundeep , Spelsberg, Thomas C., Turner, Russell T. , Iwaniec, Urszula T. , Lydon, John P. , Khosla, Sundeep

Mayo Clinic

Endocrinology | February 14, 2008 | Volume: 149 | Issue: 5 | Pages: 2383-2390

10.1210/en.2007-1247 | PMID 18276762 Get It

Altered neuronal gene expression in brain regions differentially affected by Alzheimer's disease: a reference data set
Liang, Winnie S. , Dunckley, Travis , Beach, Thomas G. , Grover, Andrew, Mastroeni, Diego , Ramsey, Keri , Caselli, Richard J. , Kukull, Walter A. , McKeel, Daniel W., Morris, John C. , Hulette, Christine M., Schmechel, Donald E., Reiman, Eric M. , Rogers, Joseph, Stephan, Dietrich A. , Morris, John C

Mayo Clinic

Physiological Genomics | February 12, 2008 | Volume: 33 | Issue: 2 | Pages: 240-256

10.1152/physiolgenomics.00242.2007 | PMID 18270320 Get It

Alzheimer's Disease (AD) is the most widespread form of dementia during the later stages of life. If improved therapeutics are not developed, the prevalence of AD will drastically increase in the coming years as the world's population ages. By identifying differences in neuronal gene expression profiles between healthy elderly persons and individuals diagnosed with AD, we may be able to better understand the molecular mechanisms that drive AD pathogenesis, including the formation of amyloid plaques and neurofibrillary tangles. In this study, we expression profiled histopathologically normal cortical neurons collected with laser capture microdissection (LCM) from six anatomically and functionally discrete postmortem brain regions in 34 AD-afflicted individuals, using Affymetrix Human Genome U133 Plus 2.0 microarrays. These regions include the entorhinal cortex, hippocampus, middle temporal gyrus, posterior cingulate cortex, superior frontal gyrus, and primary visual cortex. This study is predicated on previous parallel research on the postmortem brains of the same six regions in 14 healthy elderly individuals, for which LCM neurons were similarly processed for expression analysis. We identified significant regional differential expression in AD brains compared with control brains including expression changes of genes previously implicated in AD pathogenesis, particularly with regard to tangle and plaque formation. Pinpointing the expression of factors that may play a role in AD pathogenesis provides a foundation for future identification of new targets for improved AD therapeutics. We provide this carefully phenotyped, laser capture microdissected intraindividual brain region expression data set to the community as a public resource.
Association of Single Nucleotide Polymorphisms in Glycosylation Genes with Risk of Epithelial Ovarian Cancer
Sellers, Thomas A. , Cunningham, Julie M. , Goode, Ellen L. , Sutphen, Rebecca , Vierkant, Robert A. , Kelemen, Linda E. , Fredericksen, Zachary S., Liebow, Mark , Pankratz, V. Shane , Hartmann, Lynn C. , Myer, Jeff, Iversen, Edwin S. , Schildkraut, Joellen M. , Phelan, Catherine, Huang, Yifan , Vierkant, Robert A

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | February 11, 2008 | Volume: 17 | Issue: 2 | Pages: 397-404

10.1158/1055-9965.epi-07-0565 | PMID 18268124 Get It

Abstract Studies suggest that underglycosylation of the cell membrane mucin MUC1 may be associated with epithelial ovarian cancer. We identified 26 genes involved in glycosylation and examined 93 single nucleotide polymorphisms (SNP) with a minor allele frequency of ≥0.05 in relation to incident ovarian cancer. Cases were ascertained at the Mayo Clinic, Rochester, MN (n = 396) or a 48-county region in North Carolina (Duke University; n = 534). Ovarian cancer–free controls (n = 1,037) were frequency matched to the cases on age, race, and residence. Subjects were interviewed to obtain data on risk factors and a sample of blood for DNA and genotyped using the Illumina GoldenGate assay. We excluded subjects and individual SNPs with genotype call rates of <90%. Data were analyzed using logistic regression, with adjustment for age and residence. We fitted dominant, log additive, and recessive genetic models. Among Caucasians, nine SNPs in eight genes were associated with risk at P < 0.05 under at least one genetic model before adjusting for multiple testing. A SNP in GALNT1 (rs17647532) was the only one that remained statistically significant after Bonferroni adjustment for multiple testing but was not statistically significant in Hardy-Weinberg equilibrium among controls. Haplotype analyses revealed a global association of GALNT1 with risk (P = 0.038, under a recessive genetic model), which largely reflected a decreased risk of one haplotype (0.10 frequency; odds ratio, 0.07; P = 0.01) compared with the most common haplotype (0.39 frequency). These results suggest that genetic polymorphisms in the glycoslyation process may be novel risk factors for ovarian cancer. (Cancer Epidemiol Biomarkers Prev 2008;17(2):397–404)
Relative Weight at Age 12 and Risk of Postmenopausal Breast Cancer
Bardia, Aditya , Vachon, Celine M. , Vierkant, Robert A. , Wang, Alice H., Hartmann, Lynn C. , Sellers, Thomas A. , Cerhan, James R. , Vachon, Celine M. , Olson, Janet E. , Cerhan, James R , Vierkant, Robert A

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | February 11, 2008 | Volume: 17 | Issue: 2 | Pages: 374-378

10.1158/1055-9965.epi-07-0389 | PMID 18250344 Get It

Abstract Background: Early adolescent weight may affect the risk of postmenopausal breast cancer, and this association may be modified by a family history of breast or ovarian cancer in a first-degree relative, and/or estrogen (ER) and progesterone (PR) receptor status of the disease. Methods: Relative weight at age 12 years (above, below, or average weight compared with peers) and family history were ascertained using a mailed questionnaire in 1986, in the Iowa Women's Health Study, a prospective cohort study of postmenopausal women. Incident breast cancer cases (including ER and PR status) were identified using the Iowa Surveillance, Epidemiology, and End Results Cancer Registry. Relative risks (RR) and 95% confidence intervals (95% CI) were estimated using Cox proportional hazards regression, and were adjusted for breast cancer risk factors, including body mass index at age 18 years and body mass index at study baseline. Results: Through 2003, 2,503 cases of postmenopausal breast cancer were identified among 35,941 women in the analytic cohort. Compared with women with average weight at age 12 years, there was no association of below average weight with risk of breast cancer (RR, 1.02; 95% CI, 0.92-1.13), whereas women with above average weight had a lower risk (RR, 0.85; 95% CI, 0.74-0.98). There was no evidence of an interaction between weight at age 12 years and family history (P = 0.44). The inverse association of above average weight with risk of breast cancer was strongest for PR− tumors (RR, 0.62; 95% CI, 0.43-0.89), intermediate for ER+ (RR, 0.80; 95% CI, 0.67-0.96) and ER− (RR, 0.77; 95% CI, 0.50-1.19) tumors, and weakest for PR+ tumors (RR, 0.90; 95% CI, 0.74-1.09). These associations were not modified by a family history (all P > 0.18). In a joint ER/PR analyses, the strongest inverse association with above average weight at age 12 years was seen for ER+/PR− (RR, 0.49; 95% CI, 0.29-0.85). Conclusion: Above average weight at age 12 years was inversely associated with risk of postmenopausal breast cancer, and was not modified by a family history of the disease. The inverse association was strongest for ER+/PR− tumors. (Cancer Epidemiol Biomarkers Prev 2008;17(2):374–8)
Genetic and Clinical Heterogeneity in eIF2B-Related Disorder
Maletkovic, Jelena , Gorospe, J. Rafael, Gordon, Erynn S. , Mintz, Michelle, Hoffman, Eric P. , Alper, Gülay, Singhal, Bhim , Amartino, Hernán , Brown, Candida, Chan, Alicia , Renaud, Deborah L. , Geraghty, Michael T. , Jensen, Lloyd, Şenbil, Nesrin , Kadom, Nadja , Nazarian, Javad , Feng, Yuanjian, Wang, Zuyi, Morizono, Hiroki , Vanderver, Adeline , Schiffmann, Raphael , Lynch, David R. , Harding, Cary O. , Hartka, Thomas , Nazarian, Javad

Mayo Clinic

Journal of Child Neurology | February 8, 2008 | Volume: 23 | Issue: 2 | Pages: 205-215

10.1177/0883073807308705 | PMID 18263758 Get It

Eukaryotic initiation factor 2B (eIF2B)-related disorders are heritable white matter disorders with a variable clinical phenotype (including vanishing white matter disease and ovarioleukodystrophy) and an equally heterogeneous genotype. We report 9 novel mutations in the EIF2B genes in our subject population, increasing the number of known mutations to more than 120. Using homology modeling, we have analyzed the impact of novel mutations on the 5 subunits of the eIF2B protein. Although recurrent mutations have been found at CpG dinucleotides in the EIF2B genes, the high incidence of private or low frequency mutations increases the challenge of providing rapid genetic confirmation of this disorder, and limits the application of EIF2B screening in cases of undiagnosed leukodystrophy.
Impact of Restricting Enrollment in Stroke Genetics Research to Adults Able to Provide Informed Consent
Chen, Donna T. , Case, L. Douglas, Brott, Thomas G. , Brown, Robert D., Silliman, Scott, Worrall, Bradford B. , Meschia, James F.

Mayo Clinic

Stroke | February 8, 2008 | Volume: 39 | Issue: 3 | Pages: 831-837

10.1161/strokeaha.107.494518 | PMID 18258838 Get It

Background and Purpose— The extent of potential consent bias in observational studies elucidating genetic and environmental contributions to ischemic stroke is largely unknown. The purpose of this study was to assess differences in stroke cohort characteristics between those who provided informed consent and those whose enrollment was authorized by surrogate decision makers. Methods— The Ischemic Stroke Genetics Study (ISGS) is a prospective, 5-center, case-control study of first-ever ischemic stroke. Demographic, clinical, and stroke characteristics were compared between cases enrolled by self versus by surrogate. Data from one site that limits enrollment only to those able to self-consent were also analyzed to compare those who enrolled with those not able to consent. Results— Overall, 10% (54 of 517) were enrolled using surrogate authorization. Self-consented and surrogate-authorized cases did not differ significantly in age, sex, or conventional risk factors. Surrogate-authorized cases had significantly more severe stroke deficits, larger infarcts, and infarcts localizing to left supratentorial regions. Similarly, at the site restricting enrollment, stroke severity and characteristics differed between self-consented individuals and those otherwise eligible but unable to provide consent. Conclusions— Failure to permit surrogate authorization in genetic studies of ischemic stroke may skew enrollment toward less severe strokes caused by smaller infarcts. This potential consent bias may undermine the ability to identify genetic determinants of risk and severity and suggests that surrogate enrollment in these studies can be ethically justifiable.
Statement of the Science Concerning Locoregional Treatments After Preoperative Chemotherapy for Breast Cancer: A National Cancer Institute Conference
Harris, Jay R., Pockaj, Barbara A. , Khouri, Nagi F., Hylton, Nola, Whelan, Timothy J. , Pierce, Lori J. , Esserman, Laura J. , Newman, Lisa A. , Smith, Barbara L. , Mamounas, Eleftherios P. , Buchholz, Thomas A. , Lehman, Constance Dobbins , Miller, Michael J. , Bear, Harry D. , Mamounas, Eleftherios P. , Esserman, Laura J , Whelan, Timothy J

Mayo Clinic

Journal of Clinical Oncology | February 7, 2008 | Volume: 26 | Issue: 5 | Pages: 791-797

10.1200/jco.2007.15.0326 | PMID 18258988 Get It

Purpose To review the state of the science with respect to diagnostic imaging and locoregional therapy for patients with breast cancer receiving preoperative chemotherapy. Methods Published data relevant to clinical staging, monitoring of tumor response, and locoregional therapy for patients with breast cancer treated with preoperative chemotherapy were reviewed. Results High-quality data from prospective randomized trials are limited. Available data suggest that locoregional therapy decisions should be based on both the pretreatment clinical extent of disease and the pathologic extent of the disease after chemotherapy. Accordingly, physical examination and imaging studies that accurately define the initial extent of disease are required before treatment. Sentinel lymph node biopsy can be performed either before or after preoperative chemotherapy for patients with clinical N0 disease. The success of breast conservation after preoperative chemotherapy depends on careful patient selection and achieving negative surgical margins. Adjuvant breast radiation is indicated for all patients treated with breast conservation. For patients treated with mastectomy, chest-wall and regional nodal radiation should be considered for those who present with clinical stage III disease or have histologically positive lymph nodes after preoperative chemotherapy. Additional prospective studies are needed to determine the value of postmastectomy radiation for patients with stage II breast cancer who have negative lymph nodes after chemotherapy. Conclusion The increased use of preoperative chemotherapy has raised new questions concerning the optimal methods to stage and monitor disease response to treatment and how to optimize locoregional treatment. The available evidence suggests that a multidisciplinary approach improves outcomes.
Therapeutic Burden in Cancer Revealed by Molecular Staging
Waldman, Scott A. , Terzic, André

Mayo Clinic

Biomarkers in Medicine | January 29, 2008 | Volume: 2 | Issue: 1 | Pages: 1-3

10.2217/17520363.2.1.1 | PMID 20477357 Get It